cept Therapeutics rporated(CORT) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING'S SYNDROME AND PROVIDES CORPORATE UPDATE • Revenue of $182.5 million, a 48 percent increase over the same period in 2023 • Increase in 2024 revenue guidance to$675 – $700 million, from$640 – $670 million • Net income per common share of$0.41 (diluted), compared to $0.28 in third quarter 2023 • Cash and investments of$547.6 million as of September 30, 2024 • R ...